Visibility audit
We map where your story already lives on the internet, what is missing, and what a stranger would find confusing—written so your board or a non-scientist advisor can grasp the gaps in one read.
For drug & biotech teams talking to investors and partners
We organize your public scientific story—on the web and with a document-grounded assistant—so investors and business partners can understand what you do before you spend another dinner re-explaining the same paper trail.
BioticaBio works with small drug and biotech companies (often run by scientists) that need investors and business partners— especially big pharmaceutical firms—to understand what they do and why it matters, using information that is already public: journal articles, patents, clinical trial listings, and the company's own website.
Why it matters: when the story is scattered, meetings stall and emails pile up. When the story is organized, the same intelligent reader gets up to speed in one sitting—and the company spends less time re-explaining.
Not a fit for every business: we focus on science-heavy companies talking to sophisticated outsiders. If that is not you, the rest of the site may still be useful background—but the offer is built for that narrow case.
The science is often solid. The problem is that the proof lives in a dozen places—papers, patents, meeting posters, university pages—and nobody has assembled it into one clear file a generalist can read in an evening. Investors and partners give up not because they are lazy, but because the story is hard to find and harder to follow.
Most clients are raising money or trying to sign a partnership with a larger company. We deliver the public-facing materials—and optional software—that make that conversation easier: organized pages, plain explanations, and (if you want it) a document-grounded assistant over the published record.
We map where your story already lives on the internet, what is missing, and what a stranger would find confusing—written so your board or a non-scientist advisor can grasp the gaps in one read.
A small set of clear public pages—overview, how the therapy works, which disease, who else is in the field, who backs the science—so a reader can go from headline to supporting detail without opening ten PDFs.
Plain-language pages (still scientifically careful) that say what is new, what is already proven in animals or patients, and what is still uncertain—so you are not relying on jargon to do the persuading.
Side-by-side comparisons to other drugs or approaches people already know—because the first question in almost every meeting is “how is this different from what exists today?”
A clear picture of which universities, inventors, and outside experts belong in your story—so credit goes to the right place and the reader stops asking “who actually owns this?”
Simple reporting on whether Google is showing your pages and what search phrases surface—so you know if the outside world is actually finding the story you published.
Software that searches your approved pile of public documents first, then drafts answers in everyday English with the sources attached—useful when someone new joins a process and you do not want to start from zero.
How the platform works →When a new investor or partner asks a hard question, someone on your team usually disappears for a day to re-read papers. This part of BioticaBio is software that searches trusted public sources first—published studies, patents, trial listings—then drafts an answer in everyday language, with the source passages attached. It is built for speed in fundraising and business development, not for replacing your scientists or your lawyers.
In one sentence
Find the right paragraphs. Then summarize them. That order matters—same as good legal research—so the machine is not inventing facts; it is organizing what already exists.
A dinner or a conference can open a door. But most of the reading happens later—alone, on a laptop. If your public pages are clear and your sources are organized, that solo reader can actually reach a view. If not, the thread goes cold even when the chemistry was fine.
Face-to-face conversation still builds trust quickly. You can read the room, answer a follow-up, and fix a misunderstanding on the spot. That is hard to replace.
After the handshake, people do homework. Independent studies of business buying behavior show that serious buyers read on their own before they commit more time. The same habit shows up in investing: associates read before partners take another meeting. Good pages and organized sources make that homework go faster.
The Sources list below points to representative third-party research (not about your company—about how buyers behave).
An illustrative evidence-room structure for a scientifically interesting, commercially easy-to-misread target: IAIP in the context of necrotizing enterocolitis. The showcase demonstrates module design, narrative sequencing, and how attribution can be tightened without hype.
Showcase evidence room
Demonstrates mechanism, indication, comparator, authorities, and synthesis pages as a navigable unit—built to be read asynchronously by investors and BD leads who may not yet connect the biology to the company name.
Read the case studyA tight loop from diagnosis to assets to measurement—designed to stay maintainable inside your team and your agency workflow.
Locate where evidence lives, where company-to-concept linkage breaks, and which entities and queries matter for your next 12–18 months.
Ship investor-legible pages and summaries that preserve technical accuracy while reducing cognitive load—mechanism, indication, comparator, authorities, synthesis.
Track indexing, impressions, and engagement as operational signals. Interpret trends cautiously; refine content when the data shows confusion or gaps.
Share your program, audience, and constraints. You will get a practical read on discoverability gaps and what an evidence room would need to cover first.